Department of Radiology, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima City 890-8544, Japan.
AJR Am J Roentgenol. 2021 Oct;217(4):888-897. doi: 10.2214/AJR.20.25430. Epub 2021 Mar 24.
Contrast-enhanced CT performed for pancreatic ductal adeno-carcinoma (PDAC) detection traditionally uses a dual-phase (pancreatic and portal venous) protocol. However, PDAC may exhibit isoattenuation in these phases, hindering detection. The purpose of this study was to assess the impact on diagnostic performance in detection of small PDAC when a delayed phase is added to dual-phase contrast-enhanced CT. A database of 571 patients who underwent triple-phase (pancreatic, portal venous, and delayed) contrast-enhanced MDCT between January 2017 and March 2020 for suspected pancreatic tumor was retrospectively reviewed. A total of 97 patients had pathologically confirmed small PDAC (mean size, 22 mm; range, 7-30 mm). Twenty control patients had no pancreatic tumor suspected on CT, on initial MRI and follow-up CT, or on MRI after 12 months or longer. Three radiologists independently reviewed dual-phase and triple-phase images. Two additional radiologists assessed tumors' visual attenuation on each phase, reaching consensus for differences. Performance of dual- and triple-phase images were compared using ROC analysis, McNemar test, and Fisher exact test. AUC was higher ( < .05) for triple-phase than dual-phase images for all observers (observer 1, 0.97 vs 0.94; observer 2, 0.97 vs 0.94; observer 3, 0.97 vs 0.95). Sensitivity was higher ( < .001) for triple-phase than dual-phase images for all observers (observer 1, 74.2% [72/97] vs 59.8% [58/97]; observer 2, 88.7% [86/97] vs 71.1% [69/97]; observer 3, 86.6% [84/97] vs 72.2% [70/97]). Specificity, PPV, and NPV did not differ between image sets for any reader ( ≥ .05). Seventeen tumors showed pancreatic phase visual isoattenuation, of which nine showed isoattenuation and eight hyperattenuation in the delayed phase. Of these 17 tumors, 16 were not detected by any observer on dual-phase images; of these 16, six were detected by at least two observers and five by at least one observer on triple-phase images. Visual attenuation showed excellent interob-server agreement (κ = 0.89-0.96). Addition of a delayed phase to pancreatic and portal venous phase CT increases sensitivity for small PDAC without loss of specificity, partly related to delayed phase hyperattenuation of some small PDACs showing pancreatic phase isoattenuation. Addition of a delayed phase may facilitate earlier PDAC detection and thus improved prognosis.
用于检测胰腺导管腺癌 (PDAC) 的传统对比增强 CT 采用双期(胰腺期和门静脉期)方案。然而,PDAC 在这些时期可能表现出等密度,从而阻碍了检测。本研究旨在评估在双期对比增强 CT 中添加延迟期时对小 PDAC 检测的诊断性能的影响。回顾性分析了 2017 年 1 月至 2020 年 3 月期间因疑似胰腺肿瘤而行三周期(胰腺期、门静脉期和延迟期)对比增强 MDCT 的 571 例患者的数据库。共有 97 例患者经病理证实为小 PDAC(平均大小 22mm;范围 7-30mm)。20 例对照患者在 CT 初始、MRI 随访或 MRI 后 12 个月或更长时间未见胰腺肿瘤。3 位放射科医生独立地评估了双期和三期图像。另外两位放射科医生评估了每个阶段肿瘤的视觉衰减情况,并对差异达成共识。使用 ROC 分析、McNemar 检验和 Fisher 精确检验比较了双期和三期图像的性能。所有观察者(观察者 1,0.97 比 0.94;观察者 2,0.97 比 0.94;观察者 3,0.97 比 0.95)的三期图像 AUC 均高于双期图像(<0.05)。所有观察者的三期图像敏感性均高于双期图像(观察者 1,74.2%[72/97]比 59.8%[58/97];观察者 2,88.7%[86/97]比 71.1%[69/97];观察者 3,86.6%[84/97]比 72.2%[70/97])(<0.001)。任何读者的图像集之间的特异性、PPV 和 NPV 均无差异(≥0.05)。17 个肿瘤在胰腺期显示出视觉等密度,其中 9 个在延迟期显示等密度,8 个显示高增强。在这 17 个肿瘤中,16 个在双期图像上未被任何观察者检测到;在这 16 个肿瘤中,有 6 个被至少两名观察者检测到,有 5 个被至少一名观察者检测到。视觉衰减具有很好的观察者间一致性(κ=0.89-0.96)。在胰腺期和门静脉期 CT 中添加延迟期可提高小 PDAC 的敏感性,而特异性无损失,部分原因是一些在胰腺期显示等密度的小 PDAC 在延迟期显示高增强。添加延迟期可能有助于更早地检测到 PDAC,从而改善预后。